Reuters logo
BRIEF-Reata Pharmaceuticals announces positive data from part one of moxie trial of omaveloxolone
June 1, 2017 / 8:10 PM / 6 months ago

BRIEF-Reata Pharmaceuticals announces positive data from part one of moxie trial of omaveloxolone

June 1 (Reuters) - Reata Pharmaceuticals:

* Reata Pharmaceuticals Inc announces positive data from part one of moxie trial of omaveloxolone for friedreich’s ataxia

* Reata Pharmaceuticals Inc- company planning to initiate part 2 of trial during second half of 2017

* Reata Pharmaceuticals Inc - ‍company planning to initiate part 2 of trial during second half of 2017​

* Trial demonstrated that in fa patients, omaveloxolone induced NRF2 and was associated with improvements in mitochondrial and neurological function Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below